ML-18

SKU: orb1302773

Description

ML-18

Research Area

Pharmacology & Drug Discovery

Key Properties

• CAS Number: 1422269-30-4
• MW: 569.65
• Purity: 98.62%
• Formula: C₃₂H₃₅N₅O₅
• SMILES: COc1ccc(cc1)C1(CNC(=O)[C@H](Cc2c[nH]c3ccccc23)NC(=O)Nc2ccc(cc2)[N+]([O-])=O)CCCCC1
• Target: Bombesin Receptor
• Solubility: DMSO:50 mg/mL (87.77 mM);10% DMSO+90% Corn Oil:2.5 mg/mL (4.39 mM)

Bioactivity

• Target IC50:
  BRS3:4.8 μM.
• In Vitro:
  ML-18, at a concentration of 16 µM, reversibly inhibits BA1 at 10 nM from increasing cytosolic Ca2+ levels and at 100 nM from inducing tyrosine phosphorylation of EGFR and ERK in lung cancer cells, using FURA2-AM-loaded lung cancer cells for the former evaluation. This compound also suppresses lung cancer cell proliferation. Furthermore, ML-18 demonstrates specific inhibition of 125I-BA1 (DTyr-Gln-Trp-Ala-Val-βAla-His-Phe-Nle-NH2)BB6-14 binding to BRS-3-expressing NCI-H1299 lung cancer cells, presenting an IC50 value of 4.8 µM. It exhibits reduced affinity towards GRPR and NMBR with IC50 values of 16 µM and over 100 µM, respectively.
• Cell Research:
  ML-18 is dissolved in DMSO at a concentration of 10 mM prior to use. Cell viability is measured using the MTT assay. NCI-H727 or NCI-H1299 cells transfected with BRS-3 are treated with ML-18 (0, 4.8, 16, 48 μM) or gefitinib added. After 2 days, 15 μL of 0.1 % MTT solution added. After 4 h, 150 μL of DMSO is added. After 16 h, the optical density at 570 nm is determined.

Storage & Handling

• Storage: Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

ML 18, ML18, ML-18, inhibit, Inhibitor, BombesinReceptor, Bombesin Receptor, BRS-3

Compound Identifiers

PubChem CID

91827363